Pharvaris (PHVS) Competitors $17.42 -0.57 (-3.17%) Closing price 04:00 PM EasternExtended Trading$17.44 +0.02 (+0.14%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. RARE, ACLX, SWTX, PTGX, SRRK, KYMR, VKTX, HCM, CRNX, and CPRXShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), HUTCHMED (HCM), Crinetics Pharmaceuticals (CRNX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors Ultragenyx Pharmaceutical Arcellx SpringWorks Therapeutics Protagonist Therapeutics Scholar Rock Kymera Therapeutics Viking Therapeutics HUTCHMED Crinetics Pharmaceuticals Catalyst Pharmaceuticals Ultragenyx Pharmaceutical (NASDAQ:RARE) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk. Does the MarketBeat Community believe in RARE or PHVS? Ultragenyx Pharmaceutical received 801 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 77.58% of users gave Ultragenyx Pharmaceutical an outperform vote while only 67.80% of users gave Pharvaris an outperform vote. CompanyUnderperformOutperformUltragenyx PharmaceuticalOutperform Votes84177.58% Underperform Votes24322.42% PharvarisOutperform Votes4067.80% Underperform Votes1932.20% Which has more risk and volatility, RARE or PHVS? Ultragenyx Pharmaceutical has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.86, indicating that its share price is 386% less volatile than the S&P 500. Does the media favor RARE or PHVS? In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Pharvaris. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 0 mentions for Pharvaris. Ultragenyx Pharmaceutical's average media sentiment score of 0.72 beat Pharvaris' score of 0.42 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Overall Sentiment Ultragenyx Pharmaceutical Positive Pharvaris Neutral Which has higher valuation & earnings, RARE or PHVS? Pharvaris has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M6.22-$569.18M-$5.88-6.26PharvarisN/AN/A-$145.24M-$3.01-5.79 Do analysts prefer RARE or PHVS? Ultragenyx Pharmaceutical currently has a consensus target price of $87.00, suggesting a potential upside of 136.22%. Pharvaris has a consensus target price of $36.20, suggesting a potential upside of 107.81%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RARE or PHVS more profitable? Pharvaris has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Pharvaris' return on equity of -54.02% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-93.04% -186.49% -36.81% Pharvaris N/A -54.02%-50.36% Do insiders and institutionals have more ownership in RARE or PHVS? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryUltragenyx Pharmaceutical beats Pharvaris on 11 of the 17 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$940.70M$2.82B$5.37B$8.55BDividend YieldN/A2.69%5.38%4.23%P/E Ratio-5.7921.1225.6619.26Price / SalesN/A294.12399.40109.24Price / CashN/A40.9225.4426.73Price / Book3.147.337.885.66Net Income-$145.24M-$55.10M$3.15B$248.36M7 Day Performance2.71%-3.29%-1.60%-0.26%1 Month Performance8.94%5.05%3.29%3.65%1 Year Performance-8.56%-2.40%41.13%15.38% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris1.3824 of 5 stars$17.42-3.2%$36.20+107.8%-5.6%$940.70MN/A-5.7930RAREUltragenyx Pharmaceutical4.1737 of 5 stars$37.11-1.0%$88.77+139.2%-6.2%$3.54B$590.69M-5.851,310Analyst ForecastACLXArcellx2.2814 of 5 stars$64.09-2.9%$111.33+73.7%+12.3%$3.53B$76.81M-90.2780SWTXSpringWorks Therapeutics1.5061 of 5 stars$46.87+0.2%$52.57+12.2%+30.0%$3.53B$219.67M-13.47230Positive NewsHigh Trading VolumePTGXProtagonist Therapeutics1.328 of 5 stars$54.66-3.0%$65.44+19.7%+65.3%$3.39B$207.80M20.55120SRRKScholar Rock4.3471 of 5 stars$32.13-1.0%$42.67+32.8%+302.8%$3.05B$33.19M-13.67140KYMRKymera Therapeutics3.4504 of 5 stars$46.84-0.3%$59.82+27.7%+43.4%$3.05B$58.89M-20.02170Positive NewsVKTXViking Therapeutics4.4418 of 5 stars$26.96+3.4%$87.15+223.3%-50.7%$3.03BN/A-26.9620Positive NewsHCMHUTCHMED1.3908 of 5 stars$16.79-0.7%$19.00+13.2%-17.2%$2.95B$630.20M0.001,760CRNXCrinetics Pharmaceuticals3.2107 of 5 stars$31.20-1.8%$74.56+139.0%-33.8%$2.92B$760K-8.36210CPRXCatalyst Pharmaceuticals4.9256 of 5 stars$23.67+0.6%$32.83+38.7%+44.2%$2.87B$534.65M20.0680Options Volume Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Alternatives Arcellx Alternatives SpringWorks Therapeutics Alternatives Protagonist Therapeutics Alternatives Scholar Rock Alternatives Kymera Therapeutics Alternatives Viking Therapeutics Alternatives HUTCHMED Alternatives Crinetics Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
